Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis.

De la Flor JC, Lorenzo JD, Marschall A, Valga F, Vázquez TM, Cícero ER

Case reports in nephrology and dialysis1 Sept 2022Cited by 12 (Europe PMC)

PMID36465574PMCIDPMC9710441DOI10.1159/000527919PepBankPUB-36465574

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanCase report or seriesEfficacy outcome
In 3 patients with advanced diabetic kidney disease on hemodialysis, subcutaneous semaglutide was reported to lower HbA1c during 6 months of follow-up.
In plain wordsIn 3 patients on dialysis, semaglutide was reported to lower HbA1c over 6 months.
Peptide
Semaglutide
Outcome
DecreaseHbA1c in hemodialysis patients
Study
n = 3
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
the favorable effects on glycemic control, lowering HbA1c, albuminuria, weight, blood pressure control, and preservation of residual kidney function (RKF) during a 6-month follow-up
1 context sentence(design, population, supporting numbers)
Summary · context
herein we present 3 cases of patients with advanced DKD in maintenance incremental hemodialysis with 1 session per week
Report a problemFND-3646557401
02HumanCase report or seriesEfficacy outcome
In 3 patients with advanced diabetic kidney disease on hemodialysis, subcutaneous semaglutide was reported to lower albuminuria during 6 months of follow-up.
In plain wordsIn 3 patients on dialysis, semaglutide was reported to lower albuminuria over 6 months.
Peptide
Semaglutide
Outcome
DecreaseAlbuminuria in hemodialysis patients
Study
n = 3
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
the favorable effects on glycemic control, lowering HbA1c, albuminuria, weight, blood pressure control, and preservation of residual kidney function (RKF) during a 6-month follow-up
1 context sentence(design, population, supporting numbers)
Summary · context
herein we present 3 cases of patients with advanced DKD in maintenance incremental hemodialysis with 1 session per week
Report a problemFND-3646557402
03HumanCase report or seriesEfficacy outcome
In 3 patients with advanced diabetic kidney disease on hemodialysis, subcutaneous semaglutide was reported to lower weight during 6 months of follow-up.
In plain wordsIn 3 patients on dialysis, semaglutide was reported to lower body weight over 6 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight in hemodialysis patients
Study
n = 3
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
the favorable effects on glycemic control, lowering HbA1c, albuminuria, weight, blood pressure control, and preservation of residual kidney function (RKF) during a 6-month follow-up
1 context sentence(design, population, supporting numbers)
Summary · context
herein we present 3 cases of patients with advanced DKD in maintenance incremental hemodialysis with 1 session per week
Report a problemFND-3646557403
04HumanCase report or seriesEfficacy outcome
In 3 patients with advanced diabetic kidney disease on hemodialysis, subcutaneous semaglutide was reported to have a favorable effect on blood pressure control during 6 months of follow-up.
In plain wordsIn 3 patients on dialysis, semaglutide was reported to help blood pressure control over 6 months.
Peptide
Semaglutide
Outcome
Direction not reportedBlood pressure control in hemodialysis patients
Study
n = 3
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
the favorable effects on glycemic control, lowering HbA1c, albuminuria, weight, blood pressure control, and preservation of residual kidney function (RKF) during a 6-month follow-up
1 context sentence(design, population, supporting numbers)
Summary · context
herein we present 3 cases of patients with advanced DKD in maintenance incremental hemodialysis with 1 session per week
Report a problemFND-3646557404
05HumanCase report or seriesEfficacy outcome
In 3 patients with advanced diabetic kidney disease on hemodialysis, subcutaneous semaglutide was reported to be linked to preservation of residual kidney function during 6 months of follow-up.
In plain wordsIn 3 patients on dialysis, semaglutide was reported to be linked to preserved remaining kidney function over 6 months.
Peptide
Semaglutide
Outcome
Direction not reportedPreservation of residual kidney function
Study
n = 3
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
the favorable effects on glycemic control, lowering HbA1c, albuminuria, weight, blood pressure control, and preservation of residual kidney function (RKF) during a 6-month follow-up
1 context sentence(design, population, supporting numbers)
Summary · context
herein we present 3 cases of patients with advanced DKD in maintenance incremental hemodialysis with 1 session per week
Report a problemFND-3646557405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.